Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5587_Библиотеки_им_академика_М_И_Перельмана.pdf
QSAR Studies on Bacterial Efux Pump Inhibitors
network methods which can deal with non-linear structure-activity relationships. These approaches may
pave the way for the establishment of rapid in silico screening that are routinely applied in the early drug
discovery phase. Additionally, pharmacophore modeling should also be considered in such the cases
where the database includes a large number of compounds that have diverse structural properties. This
method may be used alongside 3D-QSAR in order to assess the drug – transporter interactions, and also to
give certain suggestions on the direction of synthesizing new chemical compounds to inhibit the studied
efflux pumps. The pharmacophore models can be derived from either the binding site of the protein or
a group of active compounds (Guner, 2000; Mannhold, Kubinyi, Folkers, Langer, & Hoffmann, 2006).
Recently, many researchers are working on the efflux pump namely NorA of S. aureus. However, no
X-ray crystal structures have been found until now. Hence, physiological, pharmacological and medicinal
chemistry studies on NorA pump have contributed to our understanding of the structure and mechanism
of drug resistance. Further in silico as well as in vitro studies and X-ray crystal structures of certain ef-
flux pumps like NorA have remained attractive targets to scientist working in intelligent designs of new
novel NorA inhibitors as well as other EPIs.
CONCLUDING REMARKS
This review provides a summary of current knowledge about efflux-pump-mediated multidrug resistance and QSAR studies on bacterial EPIs. QSAR modeling results provide useful information for
structural modifications of existing compounds in order to gain more potent compounds in use. The
major benefits derived from developing efficient EPIs will be the ability to reuse various antibiotics
affected by the efflux pumps as well as the control of the emergence and the dissemination of MDR
efflux strains. Until now, the majority of the known inhibitors have been obtained from screening
libraries of synthetic compounds, from purification of natural compounds or chemical modification
of existing molecules.
As far as Gram-positive bacteria are concerned, most of the QSAR studies on bacterial MDR are
dedicated to NorA in S.aureus. Obtained QSAR analyses, coupled with molecular docking studies,
proved that hydrophobicity and hydrogen bondings are essential for NorA inhibitory activity. For
Gram-negative bacterial EPIs, there has been a modest number of QSAR studies conducted. With the
advent of high-resolution crystal structures of efflux pumps of Escherichia coli and Pseudomonas
aeruginosa, it is hoped that consequent increase in the population of identified molecules with high
EPI capacity would foster ligand-based approaches in this area. For general QSAR studies on bacterial EPIs, 2D-QSAR using partial least squares method and molecular field parameters were largely
employed. Therefore, it is suggested that 3D-QSAR and machine learning methods should be taken
into consideration when generating future QSAR models. Also, additional X-ray structures of proteins
will definitely aid in the understanding of the molecular principles underlying the ligand-protein binding mode of bacterial efflux pumps.
To date, none of bacterial EPIs have entered clinical trials yet, the active compounds found with
EPI-potency should still be subjects of deeper examination, including their pharmacokinetic properties and toxicity, as they give a hope for their future therapeutic usage. Moreover, the development
of combination therapy poses additional complexity due to the necessity of precision tailoring of the
pharmacokinetics of both agents to achieve the desired pharmacodynamic effect.
256
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
QSAR Studies on Bacterial Efux Pump Inhibitors
ACKNOWLEDGMENT
This work was supported by the Vietnam’s National Foundation for Science and Technology Development - NAFOSTED (Grant # 106.99-2012.106 to Khac-Minh Thai).
REFERENCES
Akama, H., Kanemaki, M., Yoshimura, M., Tsukihara, T., Kashiwagi, T., & Yoneyama, H. etal. (2004).
Crystal structure of the drug discharge outer membrane protein, OprM, of Pseudomonas aeruginosa dual
modes of membrane anchoring and occluded cavity end. The Journal of Biological Chemistry, 279(51),
52816–52819. doi:10.1074/jbc.C400445200 PMID:15507433
Alekshun, M., & Nelson, M. (2004). WO patent no. 2004062674.
Ambrus, J. I., Kelso, M. J., Bremner, J. B., Ball, A. R., Casadei, G., & Lewis, K. (2008). Structure–activity
relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus. Bioorganic
& Medicinal Chemistry Letters, 18(15), 4294–4297. doi:10.1016/j.bmcl.2008.06.093 PMID:18632270
Aparna, V., Dineshkumar, K., Mohanalakshmi, N., Velmurugan, D., & Hopper, W. (2014). Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas
aeruginosa using In Silico high-throughput virtual screening and In Vitro validation. PLoS ONE, 9(7),
e101840. doi:10.1371/journal.pone.0101840 PMID:25025665
Aparna, V., Mohanalakshmi, N., Dineshkumar, K., & Hopper, W. (2014). Identification of inhibitors
for RND efflux pump of Pseudomonas aeruginosa using structure-based pharmacophore modeling approach. International Journal of Pharmacy & Pharmaceutical Sciences, 6(1).
Atal, C., Zutshi, U., & Rao, P. (1981). Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. Journal of Ethnopharmacology, 4(2), 229–232. doi:10.1016/0378-8741(81)90037-4
PMID:7311598
Bachas, S., Eginton, C., Gunio, D., & Wade, H. (2011). Structural contributions to multidrug recognition in the multidrug resistance (MDR) gene regulator, BmrR. Proceedings of the National Academy
of Sciences of the United States of America, 108(27), 11046–11051. doi:10.1073/pnas.1104850108
PMID:21690368
Ball, A. R., Casadei, G., Samosorn, S., Bremner, J. B., Ausubel, F. M., Moy, T. I., & Lewis, K. (2006).
Conjugating berberine to a multidrug resistance pump inhibitor creates an effective antimicrobial. ACS
Chemical Biology, 1(9), 594–600. doi:10.1021/cb600238x PMID:17168555
Bavro, V. N., Pietras, Z., Furnham, N., Pérez-Cano, L., Fernández-Recio, J., & Pei, X. Y. etal. (2008).
Assembly and channel opening in a bacterial drug efflux machine. Molecular Cell, 30(1), 114–121.
doi:10.1016/j.molcel.2008.02.015 PMID:18406332
Bay, D. C., Rommens, K. L., & Turner, R. J. (2008). Small multidrug resistance proteins: A multidrug transporter family that continues to grow. Biomembranes, 1778(9), 1814–1838. doi:10.1016/j.
bbamem.2007.08.015
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
257
QSAR Studies on Bacterial Efux Pump Inhibitors
Belsare, D. P., Pal, S. C., Kazi, A. A., Kankate, R. S., & Vanjari, S. S. (2010). Evaluation of antioxidant
activity of chalcones and flavonoids. International Journal of ChemTech Research, 2(2), 1080–1089.
Bhardwaj, R. K., Glaeser, H., Becquemont, L., Klotz, U., Gupta, S. K., & Fromm, M. F. (2002). Piperine,
a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. The Journal of Pharma-
cology and Experimental Therapeutics, 302(2), 645–650. doi:10.1124/jpet.102.034728 PMID:12130727
Borges-Walmsley, M., McKeegan, K., & Walmsley, A. (2003). Structure and function of efflux pumps
that confer resistance to drugs. The Biochemical Journal, 376(2), 313–338. doi:10.1042/BJ20020957
PMID:13678421
Bush, K., & Miller, G. H. (1998). Bacterial enzymatic resistance: β-lactamases and aminoglycoside-modifying enzymes. Current Opinion in Microbiology, 1(5), 509–515. doi:10.1016/S1369-5274(98)80082-9
PMID:10066532
Chamberland, S., Ishida, Y., Lee, V. J., Leger, R., Nakayama, K., Ohta, T., et al. (2002). US patent no.
6399629. Washington, DC: US Patent Office.
Chang, C., Ray, A., & Swaan, P. (2005). In silico strategies for modeling membrane transporter function. Drug Discovery Today, 10(9), 663–671. doi:10.1016/S1359-6446(05)03429-X PMID:15894231
Chen, C. Y. (2011). TCM Database@Taiwan: The world’s largest traditional Chinese medicine database
for drug screening in silico. PLoS ONE, 6(1), e15939. doi:10.1371/journal.pone.0015939 PMID:21253603
Chen, J., Morita, Y., Huda, M. N., Kuroda, T., Mizushima, T., & Tsuchiya, T. (2002). VmrA, a mem-
+
ber of a novel class of Na
-coupled multidrug efflux pumps from Vibrio parahaemolyticus. Journal of
Bacteriology, 184(2), 572–576. doi:10.1128/JB.184.2.572-576.2002 PMID:11751837
Chevalier, J., Bredin, J., Mahamoud, A., Malléa, M., Barbe, J., & Pagès, J.-M. (2004). Inhibitors of
antibiotic efflux in resistant Enterobacter aerogenes and Klebsiella pneumoniae strains. Antimicrobial
Agents and Chemotherapy, 48(3), 1043–1046. doi:10.1128/AAC.48.3.1043-1046.2004 PMID:14982806
Chung, Y., & Saier, M. Jr. (2001). SMR-type multidrug resistance pumps. Current Opinion in Drug
Discovery & Development, 4(2), 237–245. PMID:11378963
Coban, A. Y., Ekinci, B., & Durupinar, B. (2004). A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy, 50(1), 22–26. doi:10.1159/000077280
PMID:15084801
Dai, Y., Zhang, X., Zhang, X., Wang, H., & Lu, Z. (2008). DFT and GA studies on the QSAR of 2-aryl5-nitro-1H-indole derivatives as NorA efflux pump inhibitors. Journal of Molecular Modeling, 14(9),
807–812. doi:10.1007/s00894-008-0328-6 PMID:18575902
Delmar, J. A., Su, C.-C., & Yu, E. W. (2014). Bacterial multidrug efflux transporters. Annual Review
of Biophysics, 43, 93-117. doi: 10.1146/annurev-biophys-051013-022855
DePristo, M. A., de Bakker, P. I., & Blundell, T. L. (2004). Heterogeneity and inaccuracy in protein
structures solved by X-ray crystallography. Structure (London, England), 12(5), 831–838. doi:10.1016/j.
str.2004.02.031 PMID:15130475
258
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
QSAR Studies on Bacterial Efux Pump Inhibitors
Du, D., Wang, Z., James, N. R., Voss, J. E., Klimont, E., & Ohene-Agyei, T. etal. (2014). Structure
of the AcrAB-TolC multidrug efflux pump. Nature, 509(7501), 512–515. doi:10.1038/nature13205
PMID:24747401
Edward, W. Y., Aires, J. R., McDermott, G., & Nikaido, H. (2005). A periplasmic drug-binding site of
the AcrB multidrug efflux pump: A crystallographic and site-directed mutagenesis study. Journal of
Bacteriology, 187(19), 6804–6815. doi:10.1128/JB.187.19.6804-6815.2005 PMID:16166543
Edward, W. Y., McDermott, G., Zgurskaya, H. I., Nikaido, H., & Koshland, D. E. (2003). Structural basis
of multiple drug-binding capacity of the AcrB multidrug efflux pump. Science, 300(5621), 976–980.
doi:10.1126/science.1083137 PMID:12738864
Elkins, C. A., & Nikaido, H. (2003). 3D structure of AcrB: The archetypal multidrug efflux transporter
of Escherichia coli likely captures substrates from periplasm. Drug Resistance Updates, 6(1), 9–13.
doi:10.1016/S1368-7646(03)00004-9 PMID:12654283
Farkas, O., Jakus, J., & Héberger, K. (2004). Quantitative structure–antioxidant activity relationships
of flavonoid compounds. Molecules (Basel, Switzerland), 9(12), 1079–1088. doi:10.3390/91201079
PMID:18007505
Ferreira, M., & Kiralj, R. (2004). QSAR study of β‐lactam antibiotic efflux by the bacterial multidrug
resistance pump AcrB. Journal of Chemometrics, 18(5), 242–252. doi:10.1002/cem.867
German, N., Kaatz, G. W., & Kerns, R. J. (2008). Synthesis and evaluation of PSSRI-based inhibitors
of Staphylococcus aureus multidrug efflux pumps. Bioorganic & Medicinal Chemistry Letters, 18(4),
1368–1373. doi:10.1016/j.bmcl.2008.01.014 PMID:18242086
Guner, O. F. (2000). Pharmacophore perception, development, and use in drug design. La Jolla, CA:
International University Line.
Handzlik, J., Matys, A., & Kieć-Kononowicz, K. (2013). Recent advances in multi-drug resistance
(MDR) efflux pump inhibitors of Gram-positive bacteria S. aureus. Antibiotics, 2(1), 28–45. doi:10.3390/
antibiotics2010028
He, X., Szewczyk, P., Karyakin, A., Evin, M., Hong, W.-X., Zhang, Q., & Chang, G. (2010). Structure
of a cation-bound multidrug and toxic compound extrusion transporter. Nature, 467(7318), 991–994.
doi:10.1038/nature09408 PMID:20861838
Higgins, C. F. (2001). ABC transporters: Physiology, structure and mechanism–an overview. Research
in Microbiology, 152(3), 205–210. doi:10.1016/S0923-2508(01)01193-7 PMID:11421269
Hinchliffe, P., Greene, N. P., Paterson, N. G., Crow, A., Hughes, C., & Koronakis, V. (2014). Structure
of the periplasmic adaptor protein from a major facilitator superfamily (MFS) multidrug efflux pump.
FEBS Letters, 588(17), 3147–3153. doi:10.1016/j.febslet.2014.06.055 PMID:24996185
Hollenstein, K., Dawson, R. J., & Locher, K. P. (2007). Structure and mechanism of ABC transporter
proteins. Current Opinion in Structural Biology, 17(4), 412–418. doi:10.1016/j.sbi.2007.07.003
PMID:17723295
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
259
QSAR Studies on Bacterial Efux Pump Inhibitors
Hvorup, R. N., Winnen, B., Chang, A. B., Jiang, Y., Zhou, X. F., & Saier, M. H. Jr. (2003). The multidrug/
oligosaccharidyl‐lipid/polysaccharide (MOP) exporter superfamily. European Journal of Biochemistry,
270(5), 799–813. doi:10.1046/j.1432-1033.2003.03418.x PMID:12603313
Inoko, H., & Yoshihara, E. (2011). 7985410. Washington, DC: US Patent Office.
Jack, D. L., Yang, N. M., & Saier, H, M. (. (2001). The drug/metabolite transporter superfamily. European
Journal of Biochemistry, 268(13), 3620–3639. doi:10.1046/j.1432-1327.2001.02265.x PMID:11432728
Jarmuła, A., Obłąk, E., Wawrzycka, D., & Gutowicz, J. (2010). Oporność wielolekowa związana z
aktywnym usuwaniem leków z komórek drobnoustrojów. Postepy higieny i medycyny doswiadczalnej
(Online), 65, 216–227. doi:10.5604/17322693.937011 PMID:21502698
Kaatz, G. W., Moudgal, V. V., Seo, S. M., Hansen, J. B., & Kristiansen, J. E. (2003). Phenylpiperidine
selective serotonin reuptake inhibitors interfere with multidrug efflux pump activity in Staphylococcus au-
reus. International Journal of Antimicrobial Agents, 22(3), 254–261. doi:10.1016/S0924-8579(03)00220-6
PMID:13678830
Kaatz, G. W., Moudgal, V. V., Seo, S. M., & Kristiansen, J. E. (2003). Phenothiazines and thioxanthenes
inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy,
47(2), 719–726. doi:10.1128/AAC.47.2.719-726.2003 PMID:12543683
Kalia, N. P., Mahajan, P., Mehra, R., Nargotra, A., Sharma, J. P., Koul, S., & Khan, I. A. (2012). Capsaicin,
a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus.
The Journal of Antimicrobial Chemotherapy, 67(10), 2401–2408. doi:10.1093/jac/dks232 PMID:22807321
Kern, W. V., Steinke, P., Schumacher, A., Schuster, S., von Baum, H., & Bohnert, J. A. (2006). Effect
of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli. The Journal of Antimicrobial Chemotherapy, 57(2),
339–343. doi:10.1093/jac/dki445 PMID:16354747
Khan, I. A., Mirza, Z. M., Kumar, A., Verma, V., & Qazi, G. N. (2006). Piperine, a phytochemical
potentiator of ciprofloxacin against Staphylococcus aureus. Antimicrobial Agents and Chemotherapy,
50(2), 810–812. doi:10.1128/AAC.50.2.810-812.2006 PMID:16436753
Kikukawa, T., Nara, T., Araiso, T., Miyauchi, S., & Kamo, N. (2006). Two-component bacterial multidrug transporter, EbrAB: Mutations making each component solely functional. Biomembranes, 1758(5),
673–679. doi:10.1016/j.bbamem.2006.04.004
Kiralj, R., & Ferreira, M. (2008). Comparative chemometric and QSAR/SAR study of structurally unrelated substrates of a MATE efflux pump VmrA from V. parahaemolyticus: Prediction of multidrug
resistance. QSAR & Combinatorial Science, 27(3), 314–329. doi:10.1002/qsar.200630164
Kolaczkowski, M., Michalak, K., & Motohashi, N. (2003). Phenothiazines as potent modulators of
yeast multidrug resistance. International Journal of Antimicrobial Agents, 22(3), 279–283. doi:10.1016/
S0924-8579(03)00214-0 PMID:13678835
260
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
QSAR Studies on Bacterial Efux Pump Inhibitors
Koronakis, V., Sharff, A., Koronakis, E., Luisi, B., & Hughes, C. (2000). Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature, 405(6789), 914–919.
doi:10.1038/35016007 PMID:10879525
Koul, S., Koul, J. L., Taneja, S. C., Dhar, K. L., Jamwal, D. S., & Singh, K. etal. (2000). Structure–activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic
microsomal constitutive and inducible cytochrome P450 activities. Bioorganic & Medicinal Chemistry,
8(1), 251–268. doi:10.1016/S0968-0896(99)00273-4 PMID:10968285
Kumar, A., Khan, I. A., Koul, S., Koul, J. L., Taneja, S. C., & Ali, I. etal. (2008). Novel structural
analogues of piperine as inhibitors of the NorA efflux pump of Staphylococcus aureus. The Journal of
Antimicrobial Chemotherapy, 61(6), 1270–1276. doi:10.1093/jac/dkn088 PMID:18334493
Kumar, S., & Varela, M. F. (2012). Biochemistry of bacterial multidrug efflux pumps. International
Journal of Molecular Sciences, 13(4), 4484–4495. doi:10.3390/ijms13044484 PMID:22605991
Lee, A., Mao, W., Warren, M. S., Mistry, A., Hoshino, K., & Okumura, R. etal. (2000). Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. Journal of
Bacteriology, 182(11), 3142–3150. doi:10.1128/JB.182.11.3142-3150.2000 PMID:10809693
Lehtinen, J., & Lilius, E.-M. (2007). Promethazine renders Escherichia coli susceptible to penicillin
G: Real-time measurement of bacterial susceptibility by fluoro-luminometry. International Journal of
Antimicrobial Agents, 30(1), 44–51. doi:10.1016/j.ijantimicag.2007.02.019 PMID:17475447
Lei, H.-T., Chou, T.-H., Su, C.-C., Bolla, J. R., Kumar, N., & Radhakrishnan, A. etal. (2014). Crystal
Structure of the Open State of the Neisseria gonorrhoeae MtrE Outer Membrane Channel. PLoS ONE,
9(6), e97475. doi:10.1371/journal.pone.0097475 PMID:24901251
Lei, H. T., Shen, Z., Surana, P., Routh, M. D., Su, C. C., Zhang, Q., & Yu, E. W. (2011). Crystal structures
of CmeR‐bile acid complexes from Campylobacter jejuni. Protein Science, 20(4), 712–723. doi:10.1002/
pro.602 PMID:21328631
Li, X.-Z., & Nikaido, H. (2009). Efflux-mediated drug resistance in bacteria. Drugs, 69(12), 1555–1623.
doi:10.2165/11317030-000000000-00000 PMID:19678712
Lin, J., Michel, L. O., & Zhang, Q. (2002). CmeABC functions as a multidrug efflux system in Campylobacter jejuni. Antimicrobial Agents and Chemotherapy, 46(7), 2124–2131. doi:10.1128/AAC.46.7.2124-
2131.2002 PMID:12069964
Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., & Lee, M. etal. (2001). Identification
and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: Novel
agents for combination therapy. Antimicrobial Agents and Chemotherapy, 45(1), 105–116. doi:10.1128/
AAC.45.1.105-116.2001 PMID:11120952
Lomovskaya, O., & Watkins, W. (2001). Inhibition of efflux pumps as a novel approach to combat
drug resistance in bacteria. Journal of Molecular Microbiology and Biotechnology, 3(2), 225–236.
PMID:11321578
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
261
QSAR Studies on Bacterial Efux Pump Inhibitors
Lu, M., Symersky, J., Radchenko, M., Koide, A., Guo, Y., Nie, R., & Koide, S. (2013). Structures of a
Na+-coupled, substrate-bound MATE multidrug transporter. Proceedings of the National Academy of Sci-
ences of the United States of America, 110(6), 2099–2104. doi:10.1073/pnas.1219901110 PMID:23341609
Lubelski, J., Konings, W. N., & Driessen, A. J. (2007). Distribution and physiology of ABC-type transporters contributing to multidrug resistance in bacteria. Microbiology and Molecular Biology Reviews,
71(3), 463–476. doi:10.1128/MMBR.00001-07 PMID:17804667
Mahamoud, A., Chevalier, J., Alibert-Franco, S., Kern, W. V., & Pagès, J.-M. (2007). Antibiotic efflux
pumps in Gram-negative bacteria: The inhibitor response strategy. The Journal of Antimicrobial Che-
motherapy, 59(6), 1223–1229. doi:10.1093/jac/dkl493 PMID:17229832
Malléa, M., Chevalier, J., Eyraud, A., & Pagès, J.-M. (2002). Inhibitors of antibiotic efflux pump in resistant Enterobacter aerogenes strains. Biochemical and Biophysical Research Communications, 293(5),
1370–1373. doi:10.1016/S0006-291X(02)00404-7 PMID:12054665
Mannhold, R., Kubinyi, H., Folkers, G., Langer, T., & Hoffmann, R. D. (2006). Pharmacophores and
pharmacophore searches. John Wiley & Sons.
Markham, P. N., & Neyfakh, A. A. (1996). Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrobial Agents and Chemotherapy,
40(11), 2673. PMID:8913490
Markham, P. N., & Neyfakh, A. A. (2001). Efflux-mediated drug resistance in Gram-positive bacteria.
Current Opinion in Microbiology, 4(5), 509–514. doi:10.1016/S1369-5274(00)00243-5 PMID:11587925
Mazzariol, A., Tokue, Y., Kanegawa, T. M., Cornaglia, G., & Nikaido, H. (2000). High-level fluoroquinolone-resistant clinical isolates of Escherichia coli overproduce multidrug efflux protein AcrA.
Antimicrobial Agents and Chemotherapy, 44(12), 3441–3443. doi:10.1128/AAC.44.12.3441-3443.2000
PMID:11083655
McMurry, L., Petrucci, R. E., & Levy, S. B. (1980). Active efflux of tetracycline encoded by four genetically different tetracycline resistance determinants in Escherichia coli. Proceedings of the National
Academy of Sciences of the United States of America, 77(7), 3974–3977. doi:10.1073/pnas.77.7.3974
PMID:7001450
Meng, J., Bai, H., Jia, M., Ma, X., Hou, Z., & Xue, X. etal. (2011). Restoration of antibiotic susceptibility in fluoroquinolone-resistant Escherichia coli by targeting acrB with antisense phosphorothioate
oligonucleotide encapsulated in novel anion liposome. The Journal of Antibiotics, 65(3), 129–134.
doi:10.1038/ja.2011.125 PMID:22186597
Michalak, K., Wesolowska, O., Motohashi, N., Molnar, J., & Hendrich, A. (2006). Interactions of phenothiazines with lipid bilayer and their role in multidrug resistance reversal. Current Drug Targets, 7(9),
1095–1105. doi:10.2174/138945006778226570 PMID:17017888
Michalet, S., Cartier, G., David, B., Mariotte, A.-M., Dijoux-franca, M.-G., & Kaatz, G. W. etal. (2007).
N-Caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorganic & Medicinal
Chemistry Letters, 17(6), 1755–1758. doi:10.1016/j.bmcl.2006.12.059 PMID:17275293
262
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
QSAR Studies on Bacterial Efux Pump Inhibitors
Molnar, J., Hever, A., Fakla, I., Fischer, J., Ocsovski, I., & Aszalos, A. (1996). Inhibition of the transport
function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant
tumor cells. Anticancer Research, 17(1A), 481–486. PMID:9066699
Munoz-Bellido, J., Munoz-Criado, S., & Garcìa-Rodrìguez, J. (2000). Antimicrobial activity of psychotropic drugs: Selective serotonin reuptake inhibitors. International Journal of Antimicrobial Agents,
14(3), 177–180. doi:10.1016/S0924-8579(99)00154-5 PMID:10773485
Murakami, S., Nakashima, R., Yamashita, E., & Yamaguchi, A. (2002). Crystal structure of bacterial multidrug efflux transporter AcrB. Nature, 419(6907), 587–593. doi:10.1038/nature01050 PMID:12374972
Nakashima, R., Sakurai, K., Yamasaki, S., Hayashi, K., Nagata, C., & Hoshino, K. etal. (2013). Structural basis for the inhibition of bacterial multidrug exporters. Nature, 500(7460), 102–106. doi:10.1038/
nature12300 PMID:23812586
Nakayama, K., Kawato, H., Watanabe, J., Ohtsuka, M., Yoshida, K.-i., & Yokomizo, Y. etal. (2004).
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 3: Optimization of
potency in the pyridopyrimidine series through the application of a pharmacophore model. Bioorganic
& Medicinal Chemistry Letters, 14(2), 475–479. doi:10.1016/j.bmcl.2003.10.060 PMID:14698185
Nargotra, A., Koul, S., Sharma, S., Khan, I., Kumar, A., & Thota, N. etal. (2009). Quantitative structure–
activity relationship (QSAR) of aryl alkenyl amides/imines for bacterial efflux pump inhibitors. European
Journal of Medicinal Chemistry, 44(1), 229–238. doi:10.1016/j.ejmech.2008.02.015 PMID:18395941
Nargotra, A., Sharma, S., Koul, J. L., Sangwan, P. L., Khan, I. A., & Kumar, A. etal. (2009). Quantitative structure activity relationship (QSAR) of piperine analogs for bacterial NorA efflux pump inhibitors. European Journal of Medicinal Chemistry, 44(10), 4128–4135. doi:10.1016/j.ejmech.2009.05.004
PMID:19523722
Nargotra, A., Sharma, S., Koul, J. L., Sangwan, P. L., Khan, I. A., & Kumar, A. etal. (2009). Quantitative structure activity relationship (QSAR) of piperine analogsfor bacterial NorA efflux pump inhibitors. European Journal of Medicinal Chemistry, 44(10), 4128–4135. doi:10.1016/j.ejmech.2009.05.004
PMID:19523722
Neu, H. C. (1992). The crisis in antibiotic resistance. Science, 257(5073), 1064–1073. doi:10.1126/science.257.5073.1064 PMID:1509257
Nikaido, H. (1996). Multidrug efflux pumps of gram-negative bacteria. Journal of Bacteriology, 178(20),
5853. PMID:8830678
Nikaido, H. (2001). Preventing drug access to targets: cell surface permeability barriers and active
efflux in bacteria. Paper presented at the Seminars in Cell & Developmental Biology. doi:10.1006/
scdb.2000.0247
Nikaido, H. (2003). Molecular basis of bacterial outer membrane permeability revisited. Microbiology and
Molecular Biology Reviews, 67(4), 593–656. doi:10.1128/MMBR.67.4.593-656.2003 PMID:14665678
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
263
QSAR Studies on Bacterial Efux Pump Inhibitors
Nikaido, H., Basina, M., Nguyen, V., & Rosenberg, E. Y. (1998). Multidrug efflux pump acrab of salmonella typhimurium excretes only those β-lactam antibiotics containing lipophilic side chains. Journal
of Bacteriology, 180(17), 4686–4692. PMID:9721312
Oethinger, M., & Levy, S. B. (2002). CA patent no. 2378883. C. I. P. Office.
Ojha, P. K., Mitra, I., Das, R. N., & Roy, K. (2011). Further exploring rm2 metrics for validation of
QSPR models. Chemometrics and Intelligent Laboratory Systems, 107(1), 194–205. doi:10.1016/j.
chemolab.2011.03.011
Omote, H., Hiasa, M., Matsumoto, T., Otsuka, M., & Moriyama, Y. (2006). The MATE proteins as
fundamental transporters of metabolic and xenobiotic organic cations. Trends in Pharmacological Sci-
ences, 27(11), 587–593. doi:10.1016/j.tips.2006.09.001 PMID:16996621
Pagès, J.-M., Masi, M., & Barbe, J. (2005). Inhibitors of efflux pumps in gram-negative bacteria. Trends
in Molecular Medicine, 11(8), 382–389. doi:10.1016/j.molmed.2005.06.006 PMID:15996519
Park, Y., Lee, Y., Kim, H., Lee, Y., Yoon, Y., & Moon, B. etal. (2006). NMR data of flavone derivatives and their anti-oxidative activities. Bulletin of the Korean Chemical Society, 27(10), 1537–1541.
doi:10.5012/bkcs.2006.27.10.1537
Paulsen, I. T., Brown, M. H., & Skurray, R. A. (1996). Proton-dependent multidrug efflux systems.
Microbiological Reviews, 60(4), 575–608. PMID:8987357
Phan, G., Benabdelhak, H., Lascombe, M.-B., Benas, P., Rety, S., & Picard, M. etal. (2010). Structural
and dynamical insights into the opening mechanism of p. aeruginosa OprM channel. Structure (London,
England), 18(4), 507–517. doi:10.1016/j.str.2010.01.018 PMID:20399187
Phosrithong, N., Samee, W., Nunthanavanit, P., & Ungwitayatorn, J. (2012). In vitro antioxidant activity
study of novel chromone derivatives. Chemical Biology & Drug Design, 79(6), 981–989. doi:10.1111/
j.1747-0285.2012.01368.x PMID:22381130
Pieroni, M., Dimovska, M., Brincat, J. P., Sabatini, S., Carosati, E., & Massari, S. etal. (2010). From
6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of
Staphylococcus aureus multidrug efflux pumps. Journal of Medicinal Chemistry, 53(11), 4466–4480.
doi:10.1021/jm1003304 PMID:20446747
Poole, K. (2000). Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrobial
Agents and Chemotherapy, 44(9), 2233–2241. doi:10.1128/AAC.44.9.2233-2241.2000 PMID:10952561
Poole, K. (2005). Efflux-mediated antimicrobial resistance. The Journal of Antimicrobial Chemotherapy,
56(1), 20–51. doi:10.1093/jac/dki171 PMID:15914491
Pos, K. M., & Diederichs, K. (2002). Purification, crystallization and preliminary diffraction studies
of AcrB, an inner-membrane multi-drug efflux protein. Acta Crystallographica. Section D, Biological
Crystallography, 58(10), 1865–1867. doi:10.1107/S0907444902013963 PMID:12351840
264
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
QSAR Studies on Bacterial Efux Pump Inhibitors
Pratim Roy, P., Paul, S., Mitra, I., & Roy, K. (2009). On two novel parameters for validation of predictive QSAR models. Molecules (Basel, Switzerland), 14(5), 1660–1701. doi:10.3390/molecules14051660
PMID:19471190
Pumbwe, L., & Piddock, L. J. (2002). Identification and molecular characterisation of CmeB,
a Campylobacter jejuni multidrug efflux pump. FEMS Microbiology Letters, 206(2), 185–189.
doi:10.1111/j.1574-6968.2002.tb11007.x PMID:11814661
Putman, M., van Veen, H. W., & Konings, W. N. (2000). Molecular properties of bacterial multidrug
transporters. Microbiology and Molecular Biology Reviews, 64(4), 672–693. doi:10.1128/MMBR.64.4.672-
693.2000 PMID:11104814
Renau, T. E., Léger, R., Flamme, E. M., Sangalang, J., She, M. W., & Yen, R. etal. (1999). Inhibitors of
efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levo-
floxacin. Journal of Medicinal Chemistry, 42(24), 4928–4931. doi:10.1021/jm9904598 PMID:10585202
Rosenbusch, J. P. (2001). Stability of membrane proteins: Relevance for the selection of appropriate
methods for high-resolution structure determinations. Journal of Structural Biology, 136(2), 144–157.
doi:10.1006/jsbi.2001.4431 PMID:11886216
Roy, K., Mitra, I., Kar, S., Ojha, P. K., Das, R. N., & Kabir, H. (2011). Comparative studies on some
metrics for external validation of QSPR models. Journal of Chemical Information and Modeling, 52(2),
396–408. doi:10.1021/ci200520g PMID:22201416
Ruiz, J. (2003). Mechanisms of resistance to quinolones: Target alterations, decreased accumulation and
DNA gyrase protection. The Journal of Antimicrobial Chemotherapy, 51(5), 1109–1117. doi:10.1093/
jac/dkg222 PMID:12697644
Sabatini, S., Gosetto, F., Serritella, S., Manfroni, G., Tabarrini, O., & Iraci, N. etal. (2012). Pyrazolo [4,
3-c][1, 2] benzothiazines 5, 5-dioxide: A promising new class of Staphylococcus aureus NorA efflux pump
inhibitors. Journal of Medicinal Chemistry, 55(7), 3568–3572. doi:10.1021/jm201446h PMID:22432682
Sabatini, S., Kaatz, G. W., Rossolini, G. M., Brandini, D., & Fravolini, A. (2008). From phenothiazine to
3-phenyl-1, 4-benzothiazine derivatives as inhibitors of the Staphylococcus aureus NorA multidrug efflux
pump. Journal of Medicinal Chemistry, 51(14), 4321–4330. doi:10.1021/jm701623q PMID:18578473
Saier, M. H. Jr. (1998). Molecular phylogeny as a basis for the classification of transport proteins from
bacteria, archaea and eukarya. Advances in Microbial Physiology, 40, 81–136. doi:10.1016/S00652911(08)60130-7 PMID:9889977
Saier, M. H. Jr, Beatty, J. T., Goffeau, A., Harley, K. T., Heijne, W., & Huang, S.-C. etal. (1999). The
major facilitator superfamily. Journal of Molecular Microbiology and Biotechnology, 1(2), 257–279.
PMID:10943556
Schindler, B. D., Jacinto, P., & Kaatz, G. W. (2013). Inhibition of drug efflux pumps in Staphylococ-
cus aureus: Current status of potentiating existing antibiotics. Future Microbiology, 8(4), 491–507.
doi:10.2217/fmb.13.16 PMID:23534361
EBSCOhost - printed on 2/14/2023 7:16 AM via . All use subject to https://www.ebsco.com/terms-of-use
265